Xeltis has completed a €3 million extension to its series B financing, bringing the total round to €30 million. The proceeds of financing extension will help accelerate Xeltis’ pipeline development on several cardiovascular indications.
In 2015, Xeltis transformed from university spin-off into one of the world’s most promising medtech startups and successfully completed the first two feasibility trials for its bioabsorbable cardiovascular device technology.
“We have further strengthened our technology potential, our finances, our executive team and our board this year” – stated CEO Laurent Grandidier – “The business and public recognitions are beginning to establish a track record.”
Read Press Release (ENGLISH) (DUTCH) (FRENCH) (GERMAN)
